Severe Hypo-[alpha]-Lipoproteinemia During Treatment With Rosiglitazone
Thiazolidinedione drugs are in widespread use for the treatment of type 2 diabetes. In addition to improving insulin sensitivity, they generally result in a modest elevation of plasma HDL cholesterol. We report three patients, all of whom had preexisting diabetic dyslipidemia, who showed a profound...
Gespeichert in:
| Veröffentlicht in: | Diabetes care 2004-11, Vol.27 (11), p.2577 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 11 |
| container_start_page | 2577 |
| container_title | Diabetes care |
| container_volume | 27 |
| creator | Sarker, Anita Semple, Robert K Dinneen, Sean F O'Rahilly, Stephen Martin, Steven C |
| description | Thiazolidinedione drugs are in widespread use for the treatment of type 2 diabetes. In addition to improving insulin sensitivity, they generally result in a modest elevation of plasma HDL cholesterol. We report three patients, all of whom had preexisting diabetic dyslipidemia, who showed a profound reduction in plasma HDL cholesterol and apolipoprotein AI levels soon after the initiation of rosiglitazone therapy. In all three patients, HDL cholesterol levels returned to normal following drug withdrawal. The fact that this phenomenon was not seen in > 1,400 patients studied in clinical trials indicates that it is likely to be rare and idiosyncratic. Until the frequency of this adverse reaction is clearer, it would seem advisable to ensure that plasma HDL cholesterol is documented before and rechecked after commencement of thiazolidinedione therapy. [PUBLICATION ABSTRACT] |
| doi_str_mv | 10.2337/diacare.27.11.2577 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_223044057</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>762367061</sourcerecordid><originalsourceid>FETCH-proquest_journals_2230440573</originalsourceid><addsrcrecordid>eNqNjbsOgjAYRjtoIl5ewKlxB0uBFGavg5OSOBhDGv2FEmhrW0z06WXwAZy-4ZycD6F5SAIaRWx5F_zGDQSUBWEY0ISxAfJIGGd-kmV0hMbW1oSQOE5TD-1O8AIDeP_Wyr_wRlf86h-EVtooB0JCKzhed0bIEucGuGtBOnwWrsJHZUXZCMc_SsIUDR-8sTD77QQttpt8tff7zrMD64padUb2qKA06s9JwqK_pC-cx0HH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223044057</pqid></control><display><type>article</type><title>Severe Hypo-[alpha]-Lipoproteinemia During Treatment With Rosiglitazone</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Sarker, Anita ; Semple, Robert K ; Dinneen, Sean F ; O'Rahilly, Stephen ; Martin, Steven C</creator><creatorcontrib>Sarker, Anita ; Semple, Robert K ; Dinneen, Sean F ; O'Rahilly, Stephen ; Martin, Steven C</creatorcontrib><description>Thiazolidinedione drugs are in widespread use for the treatment of type 2 diabetes. In addition to improving insulin sensitivity, they generally result in a modest elevation of plasma HDL cholesterol. We report three patients, all of whom had preexisting diabetic dyslipidemia, who showed a profound reduction in plasma HDL cholesterol and apolipoprotein AI levels soon after the initiation of rosiglitazone therapy. In all three patients, HDL cholesterol levels returned to normal following drug withdrawal. The fact that this phenomenon was not seen in > 1,400 patients studied in clinical trials indicates that it is likely to be rare and idiosyncratic. Until the frequency of this adverse reaction is clearer, it would seem advisable to ensure that plasma HDL cholesterol is documented before and rechecked after commencement of thiazolidinedione therapy. [PUBLICATION ABSTRACT]</description><identifier>ISSN: 0149-5992</identifier><identifier>DOI: 10.2337/diacare.27.11.2577</identifier><identifier>CODEN: DICAD2</identifier><language>eng</language><publisher>Alexandria: American Diabetes Association</publisher><subject>Cholesterol ; Clinical outcomes ; Clinical trials ; Diabetes ; Drug therapy ; Medical treatment</subject><ispartof>Diabetes care, 2004-11, Vol.27 (11), p.2577</ispartof><rights>Copyright American Diabetes Association Nov 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27925,27926</link.rule.ids></links><search><creatorcontrib>Sarker, Anita</creatorcontrib><creatorcontrib>Semple, Robert K</creatorcontrib><creatorcontrib>Dinneen, Sean F</creatorcontrib><creatorcontrib>O'Rahilly, Stephen</creatorcontrib><creatorcontrib>Martin, Steven C</creatorcontrib><title>Severe Hypo-[alpha]-Lipoproteinemia During Treatment With Rosiglitazone</title><title>Diabetes care</title><description>Thiazolidinedione drugs are in widespread use for the treatment of type 2 diabetes. In addition to improving insulin sensitivity, they generally result in a modest elevation of plasma HDL cholesterol. We report three patients, all of whom had preexisting diabetic dyslipidemia, who showed a profound reduction in plasma HDL cholesterol and apolipoprotein AI levels soon after the initiation of rosiglitazone therapy. In all three patients, HDL cholesterol levels returned to normal following drug withdrawal. The fact that this phenomenon was not seen in > 1,400 patients studied in clinical trials indicates that it is likely to be rare and idiosyncratic. Until the frequency of this adverse reaction is clearer, it would seem advisable to ensure that plasma HDL cholesterol is documented before and rechecked after commencement of thiazolidinedione therapy. [PUBLICATION ABSTRACT]</description><subject>Cholesterol</subject><subject>Clinical outcomes</subject><subject>Clinical trials</subject><subject>Diabetes</subject><subject>Drug therapy</subject><subject>Medical treatment</subject><issn>0149-5992</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNjbsOgjAYRjtoIl5ewKlxB0uBFGavg5OSOBhDGv2FEmhrW0z06WXwAZy-4ZycD6F5SAIaRWx5F_zGDQSUBWEY0ISxAfJIGGd-kmV0hMbW1oSQOE5TD-1O8AIDeP_Wyr_wRlf86h-EVtooB0JCKzhed0bIEucGuGtBOnwWrsJHZUXZCMc_SsIUDR-8sTD77QQttpt8tff7zrMD64padUb2qKA06s9JwqK_pC-cx0HH</recordid><startdate>20041101</startdate><enddate>20041101</enddate><creator>Sarker, Anita</creator><creator>Semple, Robert K</creator><creator>Dinneen, Sean F</creator><creator>O'Rahilly, Stephen</creator><creator>Martin, Steven C</creator><general>American Diabetes Association</general><scope>3V.</scope><scope>7RV</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0K</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20041101</creationdate><title>Severe Hypo-[alpha]-Lipoproteinemia During Treatment With Rosiglitazone</title><author>Sarker, Anita ; Semple, Robert K ; Dinneen, Sean F ; O'Rahilly, Stephen ; Martin, Steven C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_2230440573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Cholesterol</topic><topic>Clinical outcomes</topic><topic>Clinical trials</topic><topic>Diabetes</topic><topic>Drug therapy</topic><topic>Medical treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sarker, Anita</creatorcontrib><creatorcontrib>Semple, Robert K</creatorcontrib><creatorcontrib>Dinneen, Sean F</creatorcontrib><creatorcontrib>O'Rahilly, Stephen</creatorcontrib><creatorcontrib>Martin, Steven C</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Agricultural Science Database</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>Diabetes care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sarker, Anita</au><au>Semple, Robert K</au><au>Dinneen, Sean F</au><au>O'Rahilly, Stephen</au><au>Martin, Steven C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Severe Hypo-[alpha]-Lipoproteinemia During Treatment With Rosiglitazone</atitle><jtitle>Diabetes care</jtitle><date>2004-11-01</date><risdate>2004</risdate><volume>27</volume><issue>11</issue><spage>2577</spage><pages>2577-</pages><issn>0149-5992</issn><coden>DICAD2</coden><abstract>Thiazolidinedione drugs are in widespread use for the treatment of type 2 diabetes. In addition to improving insulin sensitivity, they generally result in a modest elevation of plasma HDL cholesterol. We report three patients, all of whom had preexisting diabetic dyslipidemia, who showed a profound reduction in plasma HDL cholesterol and apolipoprotein AI levels soon after the initiation of rosiglitazone therapy. In all three patients, HDL cholesterol levels returned to normal following drug withdrawal. The fact that this phenomenon was not seen in > 1,400 patients studied in clinical trials indicates that it is likely to be rare and idiosyncratic. Until the frequency of this adverse reaction is clearer, it would seem advisable to ensure that plasma HDL cholesterol is documented before and rechecked after commencement of thiazolidinedione therapy. [PUBLICATION ABSTRACT]</abstract><cop>Alexandria</cop><pub>American Diabetes Association</pub><doi>10.2337/diacare.27.11.2577</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-5992 |
| ispartof | Diabetes care, 2004-11, Vol.27 (11), p.2577 |
| issn | 0149-5992 |
| language | eng |
| recordid | cdi_proquest_journals_223044057 |
| source | EZB-FREE-00999 freely available EZB journals |
| subjects | Cholesterol Clinical outcomes Clinical trials Diabetes Drug therapy Medical treatment |
| title | Severe Hypo-[alpha]-Lipoproteinemia During Treatment With Rosiglitazone |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T14%3A44%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Severe%20Hypo-%5Balpha%5D-Lipoproteinemia%20During%20Treatment%20With%20Rosiglitazone&rft.jtitle=Diabetes%20care&rft.au=Sarker,%20Anita&rft.date=2004-11-01&rft.volume=27&rft.issue=11&rft.spage=2577&rft.pages=2577-&rft.issn=0149-5992&rft.coden=DICAD2&rft_id=info:doi/10.2337/diacare.27.11.2577&rft_dat=%3Cproquest%3E762367061%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223044057&rft_id=info:pmid/&rfr_iscdi=true |